11/18
11:38 am
lenz
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
Low
Report
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
11/12
08:00 am
lenz
LENZ Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
LENZ Therapeutics to Participate in Upcoming Investor Conferences
11/11
01:39 pm
lenz
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know [Yahoo! Finance]
Neutral
Report
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know [Yahoo! Finance]
11/7
04:11 pm
lenz
LENZ Therapeutics, Inc. (NASDAQ: LENZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Medium
Report
LENZ Therapeutics, Inc. (NASDAQ: LENZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
11/6
07:00 am
lenz
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
High
Report
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
10/30
08:00 am
lenz
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
Low
Report
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
10/28
02:04 pm
lenz
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships [Yahoo! Finance]
Low
Report
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships [Yahoo! Finance]
10/27
09:00 pm
lenz
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
Medium
Report
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
10/21
08:00 am
lenz
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
Medium
Report
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
10/15
08:00 am
lenz
Lucy Therapeutics Appoints Kim Drapkin as Board Chair
Low
Report
Lucy Therapeutics Appoints Kim Drapkin as Board Chair
9/30
08:00 am
lenz
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
Low
Report
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
9/27
07:41 am
lenz
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at Raymond James. They set an "outperform" rating and a $37.00 price target on the stock.
Medium
Report
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at Raymond James. They set an "outperform" rating and a $37.00 price target on the stock.